scispace - formally typeset
D

Dan T. Vogl

Researcher at University of Pennsylvania

Publications -  174
Citations -  13563

Dan T. Vogl is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 43, co-authored 160 publications receiving 11433 citations. Previous affiliations of Dan T. Vogl include Memorial Sloan Kettering Cancer Center & Columbia University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P. Rapoport, +34 more
- 20 Jul 2015 - 
TL;DR: NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Journal ArticleDOI

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

Thomas Condamine, +29 more
- 05 Aug 2016 - 
TL;DR: A specific marker of human PMN-MDSC associated with ER stress and lipid metabolism is identified, which provides new insights into the biology and potential therapeutic targeting of these cells.
Journal ArticleDOI

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Alfred L. Garfall, +15 more
- 09 Sep 2015 - 
TL;DR: A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy and autOLOGous stem-cell transplantation, which led to a complete response.
Journal ArticleDOI

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Adam D. Cohen, +21 more
- 03 Jun 2019 - 
TL;DR: CART-BCMA infusions with or without lymphodepleting chemotherapy are clinically active in heavily-pretreated MM patients, and were associated with CD4:CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the pre-manufacturing leukapheresis product.